PRINIVIL TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Nopērc to tagad

Produkta apraksts Produkta apraksts (SPC)
29-08-2016

Aktīvā sastāvdaļa:

LISINOPRIL

Pieejams no:

MERCK CANADA INC

ATĶ kods:

C09AA03

SNN (starptautisko nepatentēto nosaukumu):

LISINOPRIL

Deva:

5MG

Zāļu forma:

TABLET

Kompozīcija:

LISINOPRIL 5MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

28/100

Receptes veids:

Prescription

Ārstniecības joma:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Produktu pārskats:

Active ingredient group (AIG) number: 0121550003; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2015-03-02

Produkta apraksts

                                PRODUCT MONOGRAPH
PRINIVIL
®
(lisinopril tablets, Merck Standard)
Tablets 5, 10 and 20 mg
PHARMACOLOGICAL CLASSIFICATION
ANGIOTENSIN-CONVERTING ENZYME INHIBITOR
MERCK CANADA INC.
DATE OF REVISION:
16750 route Transcanadienne
August 29, 2016
Kirkland, QC Canada
H9H 4M7
CONTROL NO.: 194510
1
PRODUCT MONOGRAPH
NAME OF DRUG
PRINIVIL
®
(lisinopril tablets, Merck Standard)
Tablets 5, 10 and 20 mg
PHARMACOLOGICAL CLASSIFICATION
Angiotensin-Converting Enzyme Inhibitor
ACTION AND CLINICAL PHARMACOLOGY
PRINIVIL
®
(lisinopril tablets) is an angiotensin-converting enzyme (ACE)
inhibitor which is used in
the treatment of hypertension, congestive heart failure and following
myocardial infarction in
hemodynamically stable patients.
Angiotensin-converting enzyme is a peptidyl dipeptidase which
catalyzes the conversion of
angiotensin I to the pressor substance, angiotensin II. Inhibition of
ACE results in decreased
plasma angiotensin II, which leads to increased plasma renin activity
(due to removal of negative
feedback of renin release) and decreased aldosterone secretion.
Although the latter decrease is
small, it results in a small increase in serum K
+
. In patients treated with PRINIVIL
®
and a thiazide
diuretic there was essentially no change in serum potassium (see
PRECAUTIONS).
2
ACE is identical to kininase II. Thus, PRINIVIL
®
may also block the degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of
PRINIVIL
®
is unknown.
While the mechanism through which PRINIVIL
®
lowers blood pressure is believed to be primarily
the suppression of the renin-angiotensin-aldosterone system, PRINIVIL
®
also lowers blood
pressure in patients with low-renin hypertension.
PHARMACODYNAMICS
Administration of PRINIVIL
®
to patients with hypertension results in a reduction of both supine
and
standing blood pressure. Abrupt withdrawal of PRINIVIL
®
has not been associated with a rapid
increase in blood pressure. In most patients studied, after oral
administration of an i
                                
                                Izlasiet visu dokumentu
                                
                            

Dokumenti citās valodās

Produkta apraksts Produkta apraksts franču 29-08-2016

Meklēt brīdinājumus, kas saistīti ar šo produktu

Skatīt dokumentu vēsturi